Genetic Predisposition to Disease

22

Review clinical trials related to Genetic Predisposition to Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure

This study consists of two sub-studies. Study 1 investigates gene expression related to the development of hypertension in Thailand, and Study 2 examines the effectiveness of the 4-7-8 breathing technique in reducing blood pressure in individuals with hypertension.

Participants needed: 200
Trial details
Age: 18-59Biological sex: AllType: InterventionalSponsor: Burapha UniversityUpdated: May 11, 2026Locations: 1
Eligibility criteria

Group of individuals with hypertension [+5]

Has heart disease, such as valvular stenosis or regurgitation, coronary artery d... [+19]

Status: Recruiting

Germline Testing for Predisposition to Myeloid Malignancies

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Christopher ReillyUpdated: Apr 24, 2026Locations: 1
Eligibility criteria

Age of 18 years or older [+2]

Participants who cannot safely undergo clinically indicated skin biopsy as adjud... [+1]

Status: Recruiting

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS). The name of the intervention used in this research study is: Nest portal (electronic platform for patients and clinicians)

Participants needed: 40
Trial details
Age: 18-39Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Apr 24, 2026Locations: 1
Eligibility criteria

Ages 18-39 years, inclusive. [+16]

Status: Recruiting

Helix Research Network

The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.

Participants needed: 2,000,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Helix, IncUpdated: Mar 23, 2026Locations: 14
Eligibility criteria

18 years and older [+1]

History of allogenic bone marrow transplant [+2]

Status: Recruiting

Microbiome and Association With Implant Infections

The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abundance across samples. The investigator hypothesizes that participants undergoing mastectomy with high initial abundance of Staphylococcus and/or Pseudomonas are more likely to develop subsequent tissue expander-related infections from these respective organisms.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of California, San FranciscoUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

Patients must have histologically confirmed breast malignancy OR genetic predisp... [+4]

Any significant medical condition or laboratory abnormalities, which places the... [+5]

Status: Recruiting

The China Neonatal Genomes Project

The project will carry out the genetic testing of 100000 neonates in the next 5 years. The aim of the project is to construct the Chinese neonatal genome database, establish the genetic testing standard of neonatal genetic diseases, and promote the industrialization of neonatal genetic disease gene testing, improve the training system for genetic counseling.

Participants needed: 100,000
Trial details
Age: Up to 28Biological sex: AllType: ObservationalSponsor: Children's Hospital of Fudan UniversityUpdated: Mar 16, 2026Locations: 1
Eligibility criteria

1. Both parents are of Chinese origin; [+3]

1. the nationality of one of the parents is not the Han nationality or other nat... [+6]

Status: Recruiting

Assesment of Multiomics Profiles in Health and Disease.

This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype.

Participants needed: 1,100
Trial details
Age: 18-68Biological sex: AllType: ObservationalSponsor: The Institute of Molecular and Translational Medicine, Czech RepublicUpdated: Feb 13, 2026Locations: 1
Eligibility criteria

age 18 - 68 years [+3]

not complying with inclusion criteria

Status: Recruiting

Healthy Volunteers Study

The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will be collected from healthy volunteers, or those without a known ovarian cancer diagnosis or genetic ovarian cancer risk. These samples will be compared to samples from participants with increased cancer risk and ovarian cancer diagnoses.

Participants needed: 50
Trial details
Age: 30-50Biological sex: FemaleType: ObservationalSponsor: Abramson Cancer Center at Penn MedicineUpdated: Feb 5, 2026Locations: 1
Eligibility criteria

has ovaries

genetic mutations which increase risk of ovarian cancer: BRCA1/2, BRIP1, PALB2,... [+5]

Status: Recruiting

VIGOR: Virtual Genome Center for Infant Health

This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities. The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

Participants needed: 750
Trial details
Age: 0-99Biological sex: AllType: ObservationalSponsor: Boston Children's HospitalUpdated: Feb 3, 2026Locations: 10
Eligibility criteria

Newborns presenting with probable genetic conditions inpatient on the NICU. Thes... [+2]

Presence of a likely nongenetic explanation for the phenotype (e.g., perinatal a... [+4]

Status: Recruiting

Blood Markers of Early Pancreas Cancer

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Participants needed: 1,250
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: University of NebraskaUpdated: Feb 2, 2026Locations: 1
Eligibility criteria

Age ≥19 [+3]

Personal history of pancreatic ductal adenocarcinoma (PDAC) [+2]

Status: Recruiting

Genetic Causes of Discrepant Clinic in Monogenic Twins

In the DISCO-TWIN study (prospective, open-label molecular-genetic study), twin pairs with one healthy and one affected twin with molecularly undiagnosed diseases will be analysed by means of omics technologies and/ or re-analysed using existing datasets. Phenotype and omics data will be shared within the University Hospital Tübingen and with external collaborators to improve the diagnostic rate of the subjects included in the study.

Participants needed: 50
Trial details
Biological sex: AllType: ObservationalSponsor: University Hospital TuebingenUpdated: Mar 30, 2025Locations: 1
Eligibility criteria

Twin pair monozygotic clinically (phenotypic) discordant twins [+2]

Missing informed consent of both twin/ legal representative [+1]

Status: Recruiting

Prostate Cancer Genetic Risk Evaluation and Screening Study

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Participants needed: 400
Trial details
Age: 35-74Biological sex: MaleType: ObservationalSponsor: Massachusetts General HospitalUpdated: Oct 9, 2024Locations: 1Duration: 10 Years
Eligibility criteria

Men 35-74 years old [+6]

Prior diagnosis or treatment of prostate cancer [+2]

Status: Recruiting

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation

Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value. This prospective cohort study is planning to include 182 patients with persistent atrial fibrillation, planned for electrical cardioversion, and \>18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG. An interim analysis will be conducted after more than 80 patients have been included. If the results from univariate and/or multivariable logistic regression on inflammatory markers and genetic expression regarding atrial fibrillation recurrence are significant, the study will be concluded.

Participants needed: 182
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Vrinnevi HospitalUpdated: Sep 19, 2024Locations: 2
Eligibility criteria

Persistent atrial fibrillation (ICD-10 I48.1) [+1]

Autoimmune disease [+5]

Status: Recruiting

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.

Participants needed: 4,000
Trial details
Age: 20-90Biological sex: AllType: ObservationalSponsor: Brigham and Women's HospitalUpdated: Aug 22, 2024Locations: 3
Eligibility criteria

Undergoing heart surgery [+1]

Enrolled in a concurrent drug or device trial that precludes concurrent enrollme...

Status: Recruiting

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms. The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.

Participants needed: 500
Trial details
Age: Up to 25Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Jun 26, 2024Locations: 28
Eligibility criteria

0-25 years old [+5]

Refuse to participate [+4]

Status: Recruiting

AHC Ballana Heart Study

This Study is designed to assess CVD incidence, prevalence, progression and related risk factors, including genetic background. It will provide an important base for all cardiovascular research activities in our centre and help in designing future studies and guide policy.

Participants needed: 5,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Magdi Yacoub Heart FoundationUpdated: May 29, 2024Locations: 1Duration: 30 Years
Eligibility criteria

Residents of Ballana from the 1,200 randomly selected households [+2]

Status: Recruiting

Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program

The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES). The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented. The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.

Participants needed: 12,000
Trial details
Biological sex: AllType: InterventionalSponsor: University Hospital TuebingenUpdated: Nov 29, 2023Locations: 1
Eligibility criteria

Unclear molecular cause of the disease [+1]

Missing informed consent of the patient and if applicable the legal representati... [+1]

Status: Recruiting

Mutational Oncology in Clinical Practice

The study of biological profiling is of fundamental importance in the diagnosis and treatment of many diseases, particularly oncological ones, and for this reason, the integration of molecular characterization into clinical practice becomes essential. NGS allows a high number of samples to be sequenced simultaneously, generating a great deal of genomic information in a short time and at reasonable cost. This information is of fundamental importance for the study of oncogenic drivers and gene alterations that may have a prognostic and/or predictive role in response to new molecularly targeted drugs. Policlinico A. Gemelli has begun a process of internal reorganization of the research infrastructure following its recognition in 2018 as an Institute of Hospitalization and Treatment with Scientific Character (IRCCS) for its commitment to the disciplines of "Personalized Medicine" and "Innovative Biotechnology." In particular, with regard to genomics, will be equipped with a state-of-the-art technological asset that includes a fully automated process for sample preparation and the highest gene sequencing power available today. This condition makes it possible to perform extensive genomic profiling for large numbers of patients at low cost and in reasonable time.

Participants needed: 20,000
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSUpdated: Aug 31, 2023Locations: 1
Eligibility criteria

BREAST Locally advanced or metastatic, hormone-responsive, HER2-negative breast... [+10]

Status: Not yet recruiting

Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study

Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late. Approximately 50 % of the tumours are caused by germline genetic variants screening programmes are recommended for patients and their family members; however, they are not yet well-targeted with respect to individual prognosis. In this study the investigatorscaim to characterize the genotype-phenotype associations in all Danish patients (n=400) diagnosed with PPGLs who have been followed in tertiary centres using medical records and national registries. To this end novel immunohistochemical, genetic, and epigenetic biomarkers in tumour tissues samples from biobank material (blood samples and tumour tissue) will be investigated to develop a comprehensive predictive algorithm for disease prognosis. The study will provide a clinical tool for an improved targeted screening program and subsequently prevention of disease development.

Participants needed: 400
Trial details
Age: 0-120Biological sex: AllType: ObservationalSponsor: Rigshospitalet, DenmarkUpdated: Apr 7, 2023Locations: 2
Eligibility criteria

All Danish patients diagnosed with PPGLs or genetic variants that predispose to...

None from the initial data collection. If there are no tumour tissue or blood sa...

Status: Recruiting

Aswan Heart Centre - Egyptian Healthy Volunteers

To define the genotype of a healthy Egyptian cohort as a crucial step in determining the possible clinical implications of mutations detected in patients recruited in the registry.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Magdi Yacoub Heart FoundationUpdated: Dec 22, 2022Locations: 1Duration: 5 Years
Eligibility criteria

Any adult Egyptian citizen subject that considers him/herself free of cardiovasc...

Individuals under 18 years of age [+9]

Status: Recruiting

Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

Participants needed: 270
Trial details
Age: Up to 21Biological sex: AllType: ObservationalSponsor: Sydney Children's Hospitals NetworkUpdated: Nov 4, 2022Locations: 3
Eligibility criteria

New diagnosis of malignancy [+5]

Status: Not yet recruiting

A Prognosis and Predicting Genetic Study of Lung Cancer

Lung cancer is a leading cause of cancer mortality among adults worldwide. The incidence rates of lung cancer among never smoking females in some parts of East Asia are among the highest in the world. The adenocarcinoma of lung being the most frequently identified histological type is more weakly associated with smoking, and often occurs in females and never-smokers. Although family history of lung cancer has been associated with histological subtypes, the inherited susceptibility factors that affect specific histology are unknown. Genetic factors that determine individual predisposition to lung cancer have been identified via genome-wide association studies. These known common loci, however, explain only a small fraction of the familial risk of lung cancer. The hypothesis of this study is that there are genetic factors that confer inherited susceptibility among patients with primary non-small-cell lung cancer (NSCLC).

Participants needed: 500
Trial details
Age: 20+Biological sex: AllType: ObservationalSponsor: National Taiwan University HospitalUpdated: Aug 1, 2017
Eligibility criteria

The patient's family (within third-degree relatives) has at least one diagnosed... [+1]

Patients without the diagnosis of primary non-small cell lung cancer. [+2]